Nitric oxide prevents the bacterial translocation and inhibits the systemic inflammatory response produced by implantation of a vascular prosthesis followed by Zymosan A

Inflammation Research

Volumn 54, Issue 6, 2005, Pages 261-270

  Lozano, F S ^a,b   Barros, M B ^b   Fresnadillo, M J ^a   Garcia Criado F J ^a   Gomez Alonso, A ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bacterial Translocation; NF B; Nitric Oxide; SIRS; Vascular Graft

Indexed keywords

CATALASE; CD31 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; GAMMA INTERFERON; GENTAMICIN; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MINERAL OIL; MYELOPEROXIDASE; NITRIC OXIDE; OXYGEN RADICAL; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BLOOD SAMPLING; BLOOD VESSEL PROSTHESIS; CONTROLLED STUDY; DRUG EFFICACY; ENDOPROSTHESIS; INFLAMMATION; LAPAROTOMY; MALE; MORTALITY; NONHUMAN; RAT; SURVIVAL;

ANIMALS; BACTERIAL TRANSLOCATION; BLOOD VESSEL PROSTHESIS; CATALASE; CELL ADHESION; CYTOKINES; FREE RADICALS; GLUTATHIONE PEROXIDASE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NF-KAPPA B; NITRIC OXIDE; PEROXIDASE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; SURVIVAL RATE; ZYMOSAN;

EID: 20744451070     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-005-1353-x     Document Type: Article

References (63)

1. Lozano F, Moreta S, Carbajal I, Gómez A. Consecuencias de la infección en la CAD sustitutiva de las EEII. Experiencia de 10 años en un hospital general. Cir Esp 1992; 52: 41-4.
2. Lorentzen JE, Nielsen OM, Arendrup H, Kimose HH, Bille S, Andersen J et al. Vascular graft infection: an analysis of sixty-two graft infections in 2411 consecutively implanted synthetic vascular grafts. Surgery 1985; 98: 81-6.
3. Von Asmuth EJ, Maessen JG, Van der Linden CJ. Tumor necrosis factor and interleukin 6 in a zymosan-induced shock model. Scand J Inmunol 1990; 32: 313-9.
4. Cohen JR, Sardari F, Paul J, Parikh S, Sarfati I, Danna D et al. Increased intestinal permeability: implications for thoracoabdominal aneurysm repair. Ann Vasc Surg 1992; 6: 433-7.
5. Roumen RMH, Van der Vliet A, Wevers RA, Goris RJA. Intestinal permeability is increased after mayor vascular surgery. J Vasc Surg. 1993; 17: 734-7.
6. Mora EM, Cardona MA, Simmons RL. Enteric bacteria and ingested inert particles translocate to intraperitoneal prosthetic materials. Arch Surg 1991; 126: 157-63.
7. Lau LL, Halliday MI, Lee B, Hannon RJ, Gardiner KR, Soong CV. Intestinal manipulation during elective aortic aneurysm surgery leads to portal endotoxaemia and mucosal barrier dysfunction. Eur J Vasc Endovasc Surg 2000; 19: 619-24.
8. Taner I, Ayhan M, Berkem H, Berkem R, Acar N. The presence of hemorrhagic shock increases the rate of bacterial translocation in blunt abdominal trauma. J Trauma 1998; 44: 171-4.
9. Corson RJ, Paterson IS, O'Dwyer ST, Rowland P, Kirkman E, Little RA et al. Lower limbs ischaemia and reperfusion alters gut permeability. Eur J Vasc Surg 1992; 6: 158-63.
10. Lemaire LCJM, Lanschot JJB, Stoutenbeek CP, Deventer SJH, Wells CL, Gouma DJ. Bacterial translocation in multiple organ failure: a cause or epiphenomenon still unproven. Br J Surg 1997; 84: 1340.
11. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218: 769-76.
12. Lozano FS, Criado FJG, Garcia IG, De la Espada BM, Sanchez EG, Vicente VM et al. Modelo experimental sobre translocacion bacteriana. Nutr Hosp 1993; 8: 405-10.
13. Lozano F, García-Criado FJ, Fresnadillo MJ, García E, García JE, Gomez-Alonso A. Systemic inflammatory response induced by dacron graft and modulation by antimicrobial agents: experimental study. J Surg Res 2002; 107: 7-13.
14. Payne D, Kubes P. Nitric oxide donors reduce the rise in reperfusion-induced intestinal mucosal permeability. Am J Physiol 1993; 265(Gastrointest Liver Physiol 28):G189-95.
15. Mainous MR, Tso P, Berg RD, Deitch EA. Studies of the route magnitude and time courve of bacterial translocation in a model of systemic inflammation. Arch Surg. 126:33, 1991.
16. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Meth 1985; 14: 157-67.
17. Bradley B, Stuart J, Robbins P. Carbohydrate ligands to LEC cell adhesion molecule. Cell 1990; 63: 861-5.
18. Forman HJ, Boveris A. Superoxide radical and hydrogen peroxide in mitochondria. In: Prior WA, editor. Free Radicals in Biology. New York: Academic Press, 1982: 65-90.
19. García-Criado F, Eleno N, Santos F, Valdunciel J, Reverte M, Lozano F et al. Protective effect of exogenous nitric oxide on the renal function and inflammatory response in a model of ischemia-reperfusion. Transplantation 1998; 66: 982-90.
20. Alican I, Kubes P. A critical role for nitric oxide in intestinal barrier function and dysfunction. Am J Physiol 1996; 270: G225-37.
21. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979; 23: 403-11.
22. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
23. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20: 724-6.
24. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
25. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: e85-90.
26. Kimura T, Iwase M, Kondo G, Watanabe H, Ohashi M, Ito D et al. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol 2003; 3: 1519-28.
27. Brzozowski T, Konturek PC, Konturek SJ, Kwiecien S, Sliwowski Z, Pajdo R et al. Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin. Int J Colorectal Dis 2003; 18: 320-9.
28. Decleva E, Dri P, Menegazzi R, Busetto S, Cramer R. Evidence that TNF-induced respiratory burst of adherent PMN is mediated by integrin alpha(L)beta(2). J Leukoc Biol 2002; 72: 718-26.
29. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
30. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997; 336: 1066-71.
31. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
32. Peng HB, Spiecker M, Liao JK. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol 1998; 161: 1970-6.
33. Lee JK, Choi SS, Won JS, Suh HW. The regulation of inducible nitric oxide synthase gene expression induced by lipopolysaccharide and tumor necrosis factor-alpha in C6 cells: involvement of AP-1 and NFkappaB. Life Sci 2003; 73: 595-609.
34. Adams V, Nehrhoff B, Spate U, Linke A, Schulze PC, Baur A et al. Induction of iNOS expression in skeletal muscle by IL-1beta and NFkappaB activation: an in vitro and in vivo study. Cardiovasc Res 2002; 54: 95-104.
35. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469-87.
36. Cordero Castro JL. La translocación bacteriana como fuente de contaminación e infección de prótesis vasculares. Estudio etiopatogénico [Doctoral Thesis]. Salamanca (Spain): Salamanca univ.; 1995.
37. Martín Vicente V. Modelo experimental de TB (Zymosan IP) [Doctoral Thesis]. Salamanca (Spain): Salamanca univ.; 1994.
38. Nadler EP, Ford HR. Regulation of bacterial translocation by nitric oxide. Pediatr Surg Int 2000; 16: 165-8.
39. Esteban C, Cordero JL, Gonzalez C, Benito MA, Lozano F, Gomez A. Increasing of the bacterial translocation levels with the setting of a second aggression. Cir Esp 1996; 60(Suppl): 249-50.
40. Rodriguez-Peña A, García-Criado FJ, Eleno N, Arevalo M, Lópéz-Novoa JM. Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats. Am J Transplant 2004;4:1605-13.
41. Gol MK, Nisanoglu V, Iscan Z, Balci M, Kandemir O, Tasdemir O. Inhibition of systemic inflammatory response with sodium nitroprusside in open heart surgery. J Cardiovasc Surg (Torino) 2002; 43: 803-9.
42. Eleftheriadis E, Kotzampassi K, Heliadis N, Herodotou A, Hatjopoulou E, Petridou E et al. The implication of nitric oxide in the process of bacterial translocation. Int Surg 2000; 85: 23-6.
43. Martinez-Mier G, Toledo-Pereyra LH, McDuffie JE, Warner RL, Hsiao C, Stapleton SR et al. Exogenous nitric oxide downregulates MIP-2 and MIP-1alpha chemokines and MAPK p44/42 after ischemia and reperfusion of the rat kidney. J Invest Surg 2002; 15: 287-96.
44. Martinez-Mier G, Toledo-Pereyra LH, Bussell S, Gauvin J, Vercruysse G, Arab A et al. Nitric oxide diminishes apoptosis and p53 gene expression after renal ischemia and reperfusion injury. Transplantation 2000; 70: 1431-7.
45. Lopez-Neblina F, Toledo-Pereyra LH, Mirmiran R, Paez-Rollys AJ. Time dependence of Na-nitroprusside administration in the prevention of neutrophil infiltration in the rat ischemic kidney. Transplantation 1996; 61: 179-83.
46. Marcinkiewicz J, Chain BM. Differential regulation of cytokine production by nitric oxide. Immunology 1993; 80: 146-50.
47. Marcinkiewicz J. Regulation of cytokine production by eicosanoids and nitric oxide. Arch Immunol Ther Exp (Warsz) 1997; 45: 163-7.
48. Marcinkiewicz J, Grabowska A, Chain BM. Is there a role for nitric oxide in regulation of T cell secretion of IL-2? J Immunol 1996; 156: 4617-21.
49. Giustizieri ML, Albanesi C, Scarponi C, De Pita O, Girolomoni G. Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am J Pathol 2002; 161: 1409-18.
50. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11: 66-75.
51. Fortenberry JD, Owens ML, Chen NX, Brown LAS. S-nitrosoglutathione inhibits TNF-α-induced NFκB activation in neutrophils. Inflamm Res 2001; 50: 89-95.
52. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr et al. Nitric Oxide decreases cytokine-induced endotelial activation. J Clin Invest 1995; 96: 60-8.
53. Fortenberry JD, Owens ML, Brown MR, Atkinson D, Brown LA. Exogenous nitric oxide enhances apoptotic neutrophil cell death and DNA fragmentation. Am J Respir Cell Mol Biol 1998; 18: 421-8.
54. Raychaudhuri B, Dweik R, Connors MJ, Buhrow L, Malur A, Drazba J et al. Nitric oxide blocks nuclear factor-kappaB activation in alveolar macrophages. Am J Respir Cell Mol Biol 1999; 21: 311-6.
55. West N, Guzik T, Black E, Channon K. Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase. Arteriosc Thromb Vasc Biol 2001; 21: 189-94.
56. Parratt JR. Nitric oxide. A key mediator in sepsis and endotoxaemia? J Physiol Pharmacol 1997; 48: 493-506.
57. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002; 53: 515-24.
58. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS (Lett) 1995; 364: 279-82.
59. McDonald MC, Izumi M, Cuzzocrea S, Thiemermann C. A novel, potent and selective inhibitor of the activity of inducible nitric oxide synthase (GW274150) reduces the organ injury in hemorrhagic shock. J Physiol Pharmacol 2002; 53: 555-69.
60. Ji JY, Diamond SL. Exogenous Nitric Oxide activates the endothelial glucocorticoid receptor. Biochem Biophys Res Commun 2004; 318: 192-7.
61. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-72.
62. McKay Li, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signalling pathways. Endocr Rev 1999; 20: 435-59.
63. Kuo YR, Wang FS, Jeng SF, Lutz BS, Huang HC, Yang KD. Nitrosoglutathione improves blood perfusion and flap survival by suppressing iNOS but protecting eNOS expression in the flap vessels after ischemia/reperfusion injury. Surgery 2004; 135: 43-46.